A glimpse into our pipeline - innovative ophthalmic therapies currently in development.
Science takes time. Here's what our research teams are working toward.
Next-generation osmoprotectant eye drop aimed at restoring tear film stability in severe dry eye disease.
Unit-dose prostaglandin analogue designed for patients requiring gentle, preservative-free IOP control.
Extended-duration NSAID suspension engineered to reduce dosing frequency after cataract surgery.
Balanced combination therapy targeting both ocular surface inflammation and microbial balance.
Affordable anti-VEGF option in development for retina specialists treating wet AMD and DME.
Riboflavin-based corneal collagen cross-linking solution for keratoconus management.
Distribution partnerships, pre-launch enquiries and product demonstrations - our team is ready to talk.